Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu –PSMA PET/CT) in a patient with prostate cancer | ||
| Asia Oceania Journal of Nuclear Medicine and Biology | ||
| مقاله 12، دوره 9، شماره 2، مهر 2021، صفحه 180-182 اصل مقاله (754.94 K) | ||
| نوع مقاله: Case report | ||
| شناسه دیجیتال (DOI): 10.22038/aojnmb.2021.53922.1371 | ||
| نویسندگان | ||
| Cherin Farhan؛ Siroos Mirzaei* | ||
| Institute of Nuclear Medicine with PET-Center, Klinik Ottakring, Vienna, Austria | ||
| چکیده | ||
| Prostate cancer is considered to be the most common solid cancer affecting men worldwide and leading to a significant morbidity and mortality. Metastases are usually seen in bone or lymph nodes. For recurrent disease, PET imaging with 68Ga-PSMA-11 (also known as HBED-CC, Glu-urea-Lys(Ahx)-HBED-CC, and PSMA-HBED-CC) is widely used. However, preparation of 68Ga-PSMA ligand requires the presence of radiochemistry facilities and can therefore not be utilized in centers lacking such facilities. Recently, copper labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) demonstrated promising results in patients with recurrent disease and in the primary staging of selected patients with progressive local disease. In the present case, a rare manifestation site of a metastatic lesion in a patient with advanced prostate cancer is detected by 64Cu-PSMA PET/CT. | ||
| کلیدواژهها | ||
| Prostate cancer؛ 64Cu-PSMA PET/CT؛ Penile metastasis | ||
| مراجع | ||
|
1. Pianou NK, Stavrou P, Evangelia Vlontzou M, Phivi Rondogianni M, Demetrios N, Exarhos M, et al. More advantages in detecting bone and soft tissue metastases 18 from prostate cancer using F-PSMA PET/CT. Hell J Nucl Med. 2019; 22:6-9.
2. Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. The Quarterly Journal of Nuclear Medicine and
Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of. 2015; 59(4):381-99.
3. Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. European journal of nuclear medicine and molecular imaging. 2017; 44(8):1258-68.
4. Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. 64Cu-PSMA-617 PET/CT imaging of prostate adeno-carcinoma: first in-human studies. Cancer Biotherapy and Radiopharmaceuticals. 2016; 31(8): 277-86.
5. Mirzaei S, Mohammed F, Zandieh S. Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals. Current Radio-pharmaceuticals. 2020. (E-pub Ahead of Print)
6. Mirzaei S, Revheim M-E, Raynor W, Zehetner W, Knoll P, Zandieh S, et al. 64 Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors. Oncology and therapy. 2020; 8(1):125-31.
7. Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine. 2019; 60(6):777-85.
8. Mirzaei S, Lipp RW. Peptide and pseudo-peptide (PSMA) Cu-64 radiopharmaceu-ticals. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharma-cology (IAR), [and] Section of the Society of. 2020. 64(4):364-370
9. Ramogida CF, Orvig C. Tumour targeting with radiometals for diagnosis and therapy. Chemical Communications.2013; 49(42): 4720-39. | ||
|
آمار تعداد مشاهده مقاله: 777 تعداد دریافت فایل اصل مقاله: 437 |
||